Pharmacological inhibition of USP13 induces METTL3 degradation, demonstrating therapeutic efficacy in osteosarcoma.[130] Following spinal cord injury, the USP1/UAF1 complex stabilizes METTL3 in reactive astrocytes by removing K48‐linked ubiquitination, enhancing m6A modifications on the YAP1 transcript to promote its stability and contribute to reactive astrogliosis. The gene discussed is METTL3; the disease is osteosarcoma.